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one member only had IgAN and one (or two relatives) tive treatments were very similar (i.e., 1.14 vs. 0.94 ng/mL/
had HSP. hour). Second, sodium intake was high and uncontrolled,
In our opinion, the possibility of such familial cases of allowing a lower baseline sodium excretion (intake)
IgAN and HSP can also be considered as another link before losartan treatment compared to placebo treat-
between the two diseases. ment ( sodium excretion 37 mEq/24 hours) and a higher
sodium excretion at the end of losartan treatment ( so-
Micheline Levy dium excretion 12 mEq/24 hours). Furthermore, the cir-
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cumstances of blood sampling (i.e., supine position of pa-
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de Biceˆtre, Le Kremlin-Biceˆtre, France. before taking blood samples) were not reported [1].
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Therefore, the most plausible explanation for the
plasma renin data obtained by Agarwal [1] may be meth-REFERENCES
odological shortcomings and random fluctuations, but
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expression severalfold from baseline [2]. Furthermore,
both 100 mg losartan and 80 mg quinalapril given for 10
days at this constant dose increased plasma renin activity
Reply from the author3- to 4-fold in 25 normotensive subjects on a controlled
I agree with Kra¨mer et al that the increase in plasma(low) sodium intake [3]. Finally, Stergiou et al recently
renin activity (PRA) with add-on losartan therapy wasdemonstrated that the addition of 80 mg valsartan for 5
unexpected [1]. However, I am unaware of any data inweeks to a maximal dose of chronic benazepril (20 mg
the population of patients that was studied to refute thosefor 6 weeks) significantly increased plasma renin activity
findings. Brown, Agirbasli, and Vaughan compared an-in 20 patients with primary hypertension [4].
giotensin-converting enzyme (ACE) inhibitors with an-The above results of Agarwal [1] may be explained by
giotensin II receptor blocker but did not study the combi-several shortcomings of this study. First, baseline plasma
nation in normotensive, sodium-restricted volunteers [2].renin activity before losartan treatment was 204% (!) of
In the study by Stergiou et al, benazepril was used in abaseline plasma renin activity before placebo treatment,
submaximal dose (20 mg/day) in patients with essentialwhereas plasma renin activities at the end of the respec-
hypertension [3]. In contrast, our patients received lisino-
pril for an average of 18 months in a dose of 40 mg/day
prior to participation in the trial. Such a dose is truly max- 2001 by the International Society of Nephrology
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imal, especially when considering the fact that elimina- pected. We do not have all the answers, but we speculate
on the reasons that this may have occurred [1]. Further-tion of lisinopril is predominantly renal and patients had
more, the primary end point of our trial was proteinuria,impaired glomerular filtration rates (GFR) [4]. Further-
not perturbations in renin-angiotensin system or GFR.more, our patients with chronic renal failure were con-
Thus, the results of our secondary outcomes should besuming a self-selected diet (one high in sodium), they were
considered exploratory, not definitive. We agree that ourobese, and they had poorly controlled hypertension de-
results do not fit the paradigm and that this needs furtherspite more than three medications. Therefore, this popu-
research.lation, which is reflective of a large population of the
chronic renal failure patients in the United States, is sub-
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